Targeting apoptosis in cancer chemotherapy

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 1, 2002, Pages 73-84

  Makin, Guy ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; Bcl 2 family proteins; Chemotherapy; Novel targets

Indexed keywords

ABELSON KINASE; APOPTOSIS INHIBITOR; APRIL PROTEIN; CANERTINIB; CASPASE 9; CERAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; IMATINIB; MIDOSTAURIN; OBLIMERSEN; OLIGONUCLEOTIDE; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; RAS PROTEIN; RETINOID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; COMPLEMENTARY RNA; ENZYME INHIBITOR;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL LOSS; CELL SURVIVAL; CELL VOLUME; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; LUNG ADENOCARCINOMA; MELANOMA; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHAGOCYTOSIS; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; RNA, ANTISENSE;

EID: 0036480586     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.1.73     Document Type: Review

References (89)

1. KERR JFR, WYLIE AH, CURRIE AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer (1972) 26:239-257. • The first description of apoptosis.
2. WYLIE AH: Apoptosis-cell death in tissue regulation. J. Pathol. (1987) 153:313-316.
3. HENGARTNER MO: The biochemistry of apoptosis. Nature (2000) 407:770-776. •• Excellent review of the fundamentals of apoptosis.
4. POTTEN CS: What is an apoptotic index measuring? Br. J. Cancer (1996) 74:1743-1748.
5. BROWN JM, WOUTERS BG: Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res. (1999) 59:1391-1399.
6. BROWN JM, WOUTERS BG: Does apoptosis contribute to tumor cell sensitivity to anticancer agents? In: Apoptosis and Cancer Chemother. Hickman JA, Dive C (Eds.), Humana Press, Totowa, New Jersey, USA (1999):1-19. • Two papers debating the role of apoptosis in tumour biology.
7. KAUFFMAN SH, EARNSHAW WC: Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. (2000) 256:42-49. • Good recent review.
8. TLSTY TD: Genomic instability and its role in neoplasia. Curr. Top. Microbiol. Immunol. (1997) 221: 37-46.
9. RAFF MC: Social controls on cell survival and cell death. Nature (1993) 356:397-400. •• The first suggestion of apoptosis as a default process.
10. HICKMAN JA: Apoptosis and chemotherapy resistance. Eur. J. Cancer (1996) 32:921-926. • Introducing some vital concepts with regard to the role of apoptosis in cancer chemotherapy.
11. ADAMS JM, CORY S: The Bcl-2 protein family: arbiters of cell survival. Science (1998) 281:1322-1326. •• Very important paper, responsible for the idea of Bcl-2 proteins as a control point in apoptosis.
12. CHINNAIYAN AM: The apoptosome: heart and soul of the cell death machine. Neoplasia (1999) 1:5-15.
13. BRATTON SB, COHEN GM: Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol. Sci. (2001) 22:306-315. • Detailed up to date review of current concepts of mitochondrial cytochrome c release and caspase activation.
14. GREEN DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell (2000) 102:1-4. • A typically lucid discussion of the potential roles of SMAC/DIABLO and IAPs.
15. L. Cell (1996) 87:619-628. • Important early work linking survival signalling to Bcl-2 family proteins.
16. DIJKERS PF, MEDEMA RH, LAMMERS J-WJ, KOENDERMAN L, COFFER PJ: Expression of the proapoptotic Bcl-2 family member Bim is regulated by the Forkhead transcription faaor FKHR-L1. Curr. Biol. (2000) 10:1201-1204.
17. WEI MC, ZONG W-X, CHENG EH-Y et al.: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 292:727-730.
18. LINDSTEN T, ROSS AJ, KING A et al.: The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell. (2000) 6:1389-1399.
19. ZHANG L, YU J, PARK BH, KINZLER KW, VOGELSTEIN B: Role of BAX in the apoptotic response to anticancer agents. Science (2000) 290:989-992. •• The above three papers highlight the importance of pro-apoptotic Bcl-2 family proteins in chemotherapy-induced apoptosis.
20. GILMORE AP, METCALFE AD, ROMER LH, STREULI CH: Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J. Cell Biol. (2000) 149:431-445.
21. MURPHY KM, STREIPS UN, LOCK RB: Bcl-2 inhibits a Fas-induced conformational change in the Bax N-terminus and Bax mitochondrial translocation. J. Biol. Chem. (2000) 275:17225-27228.
22. PEREZ D, WHITE E: TNF-α signals apoptosis through a Bid-dependant conformational change in Bax that is inhibited by E1B 19K. Mol. Cell (2000) 6:53-63.
23. L by tumor microenvironmental factors. J. Natl. Cancer Inst. (2000) 92:18-23.
24. DESAGHER S, OSENSAND A, NICHOLS A et al.: Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. (1999) 144:891-901.
25. GRIFFITHS GJ, DUBREZ L, JONES NH et al.: Cell damage-induced conformational changes of the pro-apoprotic protein Bak precede the onset of apoptosis. J. Cell Biol. (1999) 144:903-914. • The first evidence for the involvement of Bak in mediating drug-induced damage.
26. BOUILLET P, METCALF D, HUANG DS et al.: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (1999) 286:1735-1738. • An important paper introducing the idea of BH3-only proteins mediating disparate types of damage.
27. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al.: Constitutive activation of Stat3 signalling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105-115.
28. EPLING-BURNETTE PK, LIU JH, CATLETT-FALCONE R et al.: Inhibition of STAT3 signalling leads to apoptosis of leukemic large granular lympocytes and decreased Mcl-1 expression. J. Clin. Invest. (2001) 107:351-362.
29. YANG X-H, SLADEK TL, LIU X, BUTLER BR, FROELICH CJ, THOR AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin and etoposide-induced apoptosis. Cancer Res. (2001) 61:348-354.
30. CHANG L, KARIN M: Mammalian MAP kinase signalling cascades. Nature (2001) 410:37-40. • Recent review giving a comprehensive overview of these important signalling pathways.
31. DERIJARD B, RAINGEAUD J, BARRETT T et al.: Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 267:682-685.
32. XIA Z, DICKENS M, RATNGEAUD J, DAVIS RJ, GREENBERG ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 270:1326-1331. •• Two classic papers leading to the idea of death/survival balance.
33. TOURNIER C, HESS P, YANG DD et al.: Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (2000) 288:870-874. • Important paper linking JNK and mitochondrial mediated apoptosis.
34. DENG X, RUVOLO P, CARR B, MAY WS: Survival function of ERK1/2 as IL-3-activated staurosporine-resistant Bcl-2 kinases. Proc Natl. Acad. Sci. USA (2000) 97: 1578-1583. • The first evidence for direct effects on Bcl-2 family proteins by MAPK.
35. MACKEIGAN JP, COLLINS TS, TING JP-Y: MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. (2000) 275:38953-38956.
36. SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al.: Blockade of the MAP kinase pathway suppresses growth of colon tumours in vivo. Nat. Med. (1999) 5:810-816.
37. L. J. Exp. Med. (2000) 191:977-984.
38. DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2:561-566. • First report on the discovery and activity of STI571.
39. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukaemia. N. Eng. J. Med. (2001) 344:1031-1037.
40. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Eng. J. Med. (2001) 344:1038-1042. •• Back to back papers dealing with the clinical use of STI571.
41. JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour. N. Eng. J. Med. (2001) 344:1052-1056.
42. BRAZIL DP, HEMMINGS BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. (2001) 26:657-664. • An excellent recent review of the current state of knowledge of Akt signalling.
43. TALAPATRA S, THOMPSON CB: Growth factor signalling in cell survival: implications for cancer treatment. J. Phamacol Exp. Ther. (2001) 298:873-878. • Recent review considering the state of knowledge of therapeutic intervention in these pathways.
44. TESTA JR, BELLACOSA A: AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA (2001) 98:10983-10985. • Places Akt as a central player in carcinogenesis.
45. SHAYATESH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21:99-102.
46. TENZER A, ZINGG D, ROCHA S et al.: The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. (2001) 61:8203-8210.
47. RADIN NS: Killing cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur. J. Biochem. (2001) 268:193-204.
48. SENCHENKOV A, LITVAK DA, CABOT MC: Targeting ceramide metabolism - a strategy for overcoming drug resistance. J. Natl. Cancer Inst. (2001) 93:347-357. •• Excellent comprehensive review.
49. KOLESNIK RN, KRONKE M: Regulation of ceramide production and apoptosis. Ann. Rev. Physiol. (1998) 60:643-665.
50. HERR I, WILHELM D, BOHLER T, ANGEL P, DEBATIN KM: Activation of CD95 (APO-1/Eas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. (1997) 16:6200-6208.
51. WEIGMAN K, SCHUTZE S, MACHLEIDT T, WITTE D, KRONKE M: Functional dichotomy of neutral and acidic sphingomyelinases in tumour necrosis factor signaling. Cell (1994) 78:1005-1015.
52. ZHANG J, ALTER N, REED JC et al.: Bcl-2 interrupts the ceramide-mediated parhway of cell dearh. Proc. Natl. Acad. Sci. USA (1996) 93:5325-5328.
53. CABOT MC, GIULIANO AE, HAN TY, LIU YY: SDZ 833, the cyclosporin A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. (1999) 59:880-885.
54. CHARLES AG, HAN TY, LIU YY, HANSEN N, GIULIANO AE, CABOT MC: Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother. Pharmacol. (2001) 47:444-450.
55. MAURER BJ, MELTON L, BILLUPS C, CABOT MC, REYNOLDS CP: Synergistic cytotoxicity in solid tumour cell lines between N-(4-hydroxyphenyl)-retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (2000) 92:1897-1909.
56. GREEN DR: Apoptosis and sphingomyelin hydrolysis: the flip side. J. Cell Biol. (2000) 150:F5-F7. • Lucid review of the data regarding the timing of ceramide activation.
57. WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Onc. (2000) 18:1812-1823.
58. JANSEN B, WACHEK V, HEERE-RESS E et al.: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 356:1728-1733.
59. WANG JL, LIU D, ZHANG ZJ et al.: Structure-based discovery of an organic compound mat binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA (2000) 97:7124-7129.
60. REED JC: The survivin saga goes in vivo. J. Clin. Invest. (2001) 108:965-969. • Helpful and topical review of the state of knowledge on survivin.
61. AMBROSINI G, ADIDA C, ALTIERI DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. (1997) 3:917-921. • The first description of survivin.
62. OLIE RA, SIMÕES-WÜST P, BAUMANN B et al.: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherepy. Cancer Res. (2000) 60:2805-2809.
63. KANWAR JR, SHEN WP, KANWAR RK, BERG RW, KRISSANSE GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. (2001) 93:1541-1552.
64. GROSSMAN D, KIM PJ, SCHECHNER JS, ALTIERI DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA (2001) 98:635-640.
65. MESRI M, WALL NR, LI J, KIM RW, ALTIERI DC: Cancer gene rherapy using a survivin mutant adenovirus. J. Clin. Invest. (2001) 108:981-990.
66. KITADA S, ZAPATA JM, ANDREEFF M, REED JC: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood (2000) 96:393-397.
67. SENDEROWICZ AM: Development of cyclin-dependant kinase modulators as novel therapeutic approaches for haematological malignancies. Leukaemia (2001) 15:1-9. • Good recent review.
68. GRAVES PR, YUL, SCHWARZJKrtaZ: The Chk1 protein kinase and the Cdc25 regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. (2000) 275:5600-5605.
69. HARARI D, YARDEN Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 19:6102-6114.
70. BURRIS HA: Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin. Oncol. (2001) 28:38-44
71. ROH H, PIPPIN JA, GREEN DW et al.: HER2/neu antisense targeting of human breast carcinoma. Oncogene (2000) 19:6138-6143.
72. FRY DW: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des. (2000) 15:3-16. • Detailed review of ErbB inhibitors.
73. DEBATIN KM: The role of CD95(APO-1/ Fas) system in chemotherapy. In: Apoptosis and Cancer Chemotherapy. Hickman JA, Dive C (Eds.), Humana Press, Totowa, New Jersey, USA (1999):175-187.
74. IRMLER M, THOME M, HAHNE M et al.: Inhibition of death receptor signals by cellular FLIP. Nature (1997) 388:190-195.
75. WALCZAK H, MILLER RE, ARIAIL K et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5:157-163.
76. NAGANE M, PAN G, WEDDLE JJ et al.: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxocity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. (2000) 60:847-853.
77. NAGANE M, HUANG HJS, CAVANEE WK: The potential of TRAIL for cancer chemotherapy. Apoptosis (2001) 6:191-197. • Topical and useful review of TRAIL's potential.
78. JO M, KIM TH, SEOL DW et al.: Apoptosis induced in normal human hepatocytes by rumour necrosis factor-related apoptosis-inducing ligand. Nat. Med. (2000) 6:564-567.
79. LAWRENCE D, SHAHROKH Z, MARSTERS S et al.: Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat. Med. (2001) 7:383-385.
80. NAGY L, THOMAZY VA, HEYMAN RA, DAVIES PJA: Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Diffn. (1998) 5:11-19.
81. MELINO G, DRAOUI M, BELLINCAMPI L et al.: Retinoic acid receptors α and γ mediate the induction of tissue transglutaminase activity and apoptosis in human neuroblastoma cells. Exp. Cell Res. (1997) 235:55-61.
82. MATTHAY KK, VILLABLANCA JG, SEEGER RC et al.: Treatment of high risk neuroblastoma with intensive chemotherapy, radiorherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N. Engl. J. Med. (1999) 341:1165-1173. • Major study demonstrating the usefulness of retinoids in the clinic.
83. LOVAT PE, IRVING H, ANNICHIARICO-PETRUZZELLI M et al.: Apoptosis of N-type neuroblastoma cells with 9-cis-retinoic acid and subsequent washout. J. Natl. Cancer Inst. (1997) 89:446-452.
84. GEORGES RN, MUKHOPADHYAY T, ZHANG Y, YEN N, ROTH JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. (1993) 53:1743-1746.
85. ADJEI AA: Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. (2001) 93:1062-1074. • Up-to-date review of the state of Ras modulation in therapy.
86. PRENDERGAST GC: Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol. (2000) 12:166-173. • Excellent recent review of this exciting class of agents.
87. JIANG K, COPPOLA D, CRESPO NC et al.: The phosphoinositide 3-OH kinase/ AKT2 pathway as acritical target for farnesylrransferase inhibitor-induced apoptosis. Mol. Cell Biol. (2000) 20:139-148.
88. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2001) 100:57-70. •• Essential paper on the state of our knowledge of carcinogenesis.
89. GELMON KA, EISENHAUER EA, HARRIS AL, RATAIN MJ, WORKMAN P: Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. (1999) 91:1281-1287. * Important discussion of the problems of drug development for novel agents.